Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ACP3 | P15309 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL49659 | 0.84 | — | — | |
| SCHEMBL2651481 | 0.84 | — | — | |
| SCHEMBL2312133 | 0.84 | — | — | |
| SCHEMBL11747913 | 0.81 | TYR (0.39) | PTGS2CYP1A2CYP2C9ALDH1A1MAPK1 | |
| SCHEMBL6479076 | 0.80 | PTGS2 (0.54) | PTGS2ACP3CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL8750479 | 0.80 | PTGS2 (0.54) | PTGS2CYP1A2ACP3CHRNB2CHRNA4 | |
| SCHEMBL5865101 | 0.79 | RXRA (0.53) | PTGS2 | |
| SCHEMBL5464381 | 0.79 | PTGS2 (0.58) | PTGS2CYP1A2ACP3CHRNB2CHRNA4 | |
| SCHEMBL20833031 | 0.79 | PTGS2 (0.58) | PTGS2CYP1A2ACP3CHRNB2CHRNA4 | |
| SCHEMBL40528 | 0.79 | PTGS2 (0.58) | PTGS2CYP1A2ACP3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106748922-A | The new sulfone acid derivative of one class, its preparation method and its purposes as medicine | 中国药科大学 | 2017-05-31 | — | — | CN | claimed |
| CN-106748922-B | A kind of novel sulfone acid derivative, preparation method and its purposes as drug | 中国药科大学 | 2019-02-01 | — | — | CN | disclosed |
| CN-106748922-A | The new sulfone acid derivative of one class, its preparation method and its purposes as medicine | 中国药科大学 | 2017-05-31 | — | — | CN | disclosed |
| US-7125999-B2 | Process for producing organotitanium compound and process for addition reaction | NISSAN CHEMICAL INDUSTIES, LTD. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20040167344-A1 | Process for producing organotitanium compound and process for addition reaction | FUMIE SATO | 2004-08-26 | — | — | US | disclosed |
| US-6743916-B2 | REACTING AN ACETYLENE COMPOUND IN THE PRESENCE OF A TITANIUM COMPOUND AND GRIGNARD REAGENT TO OBTAIN ORGANOTITANIUM COMPOUND | Sato, Fumie (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20030096996-A1 | Process for producing organotitanium compound and process for addition reaction | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167344-A1 | Process for producing organotitanium compound and process for addition reaction | ZYX, H1-4, GRIA4 | PTGS2 3831/4885CYP1A2 287/4885GAA 1732/4885 |
| US-20030096996-A1 | Process for producing organotitanium compound and process for addition reaction | ZYX, H1-4, GRIA4 | PTGS2 3831/4885CYP1A2 287/4885GAA 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.